Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 16.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 89,719 shares of the company’s stock after selling 17,697 shares during the period. Principal Financial Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,617,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. FMR LLC lifted its stake in shares of Teva Pharmaceutical Industries by 49.5% during the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its position in Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock worth $621,337,000 after acquiring an additional 2,204,623 shares in the last quarter. State Street Corp boosted its holdings in Teva Pharmaceutical Industries by 10.0% in the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after acquiring an additional 1,778,268 shares during the period. Geode Capital Management LLC grew its position in Teva Pharmaceutical Industries by 3.4% in the third quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock valued at $157,571,000 after acquiring an additional 291,124 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Teva Pharmaceutical Industries by 13.4% during the second quarter. Renaissance Technologies LLC now owns 8,728,563 shares of the company’s stock valued at $141,839,000 after purchasing an additional 1,031,400 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on TEVA. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Barclays raised their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Finally, JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.88.

Insiders Place Their Bets

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Down 0.3 %

NYSE:TEVA opened at $21.24 on Friday. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company has a market capitalization of $24.06 billion, a price-to-earnings ratio of -24.99, a price-to-earnings-growth ratio of 0.99 and a beta of 0.73. Teva Pharmaceutical Industries Limited has a one year low of $10.75 and a one year high of $22.80. The stock has a 50-day simple moving average of $18.60 and a 200 day simple moving average of $17.87.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.